Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(15 sites)
United States
UCLA Health, Los Angeles, California Mission Dermatology Center, Rancho Santa Margarita, California BRCR Global, Weston, Florida IU Simon Comprehensive Cancer Center, Indianapolis, Indiana Henry Ford Cancer Institute, Detroit, Michigan University of Nebraska Medical Center, Omaha, Nebraska Morristown Medical Center / Atlantic Health System, Morristown, New Jersey Weill Cornell Medicine-New York-Presbyterian Hospital, New York, New York Gabrail Cancer Center Research, Canton, Ohio Cleveland Clinic, Cleveland, Ohio UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania Sarah Cannon Research Institute, Nashville, Tennessee Renovatio Clinical - El Paso, El Paso, Texas MD Anderson Cancer Center, Houston, Texas Renovatio Clinical - The Woodlands, The Woodlands, Texas